LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List

Stock News

2025/12/08

LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the "National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:

In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1163080994"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163080994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163080994?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163080994","market":"fut","top_or_hot":-1,"title":"LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)\" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:</p>\n<p>In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA (01513) Products Included in National Reimbursement Drug List\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-08 18:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)\" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:</p>\n<p>In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1163080994","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163080994","pubTimestamp":1765188385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01513":"丽珠医药"},"translate_title":"丽珠医药(01513)纳入国家报销药品目录的产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)\" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:\nIn 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}